You are here: Industry Insights > Blockbuster

News List

A Blockbuster to Arrive in the Multiple Sclerosis Area of China! PharmaSources/Caicai
July 24, 2019
Novartis’ Fingolimod with Annual Sales Exceeding USD3 Billion to be Marketed Soon in China
Sino Biopharmaceutical’s R&D Investment Growing by 31% to Rank Fourth! PharmaSources/Caicai
July 02, 2019
Analyze the top 10 pharmaceutical enterprises by R&D investments in 2018.
AbbVie pads Humira follow-up Skyrizi's blockbuster potential with positive 2-year data fiercepharma
June 12, 2019
AbbVie already has high hopes for newly approved immunology drug Skyrizi as its old megablockbuster Humira starts to fall.
Polyethylene Glycol Loxenatide! The First Chinese-produced Long-acting GLP-1R Agonist PharmaSources/1℃
May 29, 2019
The blockbuster diabetes product: long-acting GLP-1 receptor agonist polyethylene glycol loxenatide (trade name: Fulaimei) of Hansoh Pharmaceutical has been marketed on May 7, 2019
Novartis CEO touts 25 potential—and diverse—blockbuster launches. But is its portfolio too scattered? fiercepharma
May 29, 2019
Just over a year into his reign as Novartis CEO, Vas Narasimhan proudly spotlighted 25 potential blockbuster launches coming down the pipeline. But that figure also begs the question: Is the company dabbling in too many different therapeutic areas and pla
Super-blockbuster: Trastuzumab PharmaSources/1℃
May 14, 2019
As one of the three super-blockbusters of Roche, trastuzumab has accumulatively brought over CHF80 billion sales revenue.
AbbVie's immunology blockbuster-to-be Skyrizi picks up first global approval fiercepharma
March 27, 2019
As Humira heads toward the end of its exclusive life in the U.S. and faces new competition in Europe, AbbVie is set for its next blockbuster launch thanks to an approval in Japan.
Lilly asks migraine patients to use their imaginations in first DTC push for Emgality fiercepharma
February 18, 2019
Eli Lilly’s first effort for migraine drug Emgality had a personal connection for the director of the TV commercial.
Patient engagement as a new blockbuster drug, not quite yet, study finds worldpharmanews
November 15, 2018
"Patient engagement has featured prominently in recent healthcare research and policy, probably most notably in the Medicare Access and CHIP Reauthorization Act (MACRA) legislation.
AbbVie inks licensing deal to boost Mavyret access in nearly 100 countries fiercepharma
November 14, 2018
AbbVie has had success with its new pan-genotypic hepatitis C drug Mavyret, generating blockbuster-level sales at the expense of competitors.

Previous page 1 2 Next page